Rezvilutamide Tablets

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate Cancer (Post Prostatectomy)

Phase 2

Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy

RecruitingNCT07711314

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolProstate Cancer (Post Prostatectomy)

Start: 2026-07-01End: 2030-05-01Target: 48Updated: 2026-07-23

Phase 3

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

RecruitingNCT07241416

Jiangsu HengRui Medicine Co., Ltd.Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Start: 2025-12-05End: 2028-09-01Target: 206Updated: 2026-05-11